Commonwealth Equity Services
AVTX icon

Commonwealth Equity Services’s Avalo Therapeutics AVTX Stock Holding History

Commonwealth Equity Services’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-45
Closed -$4K – 3833
2023
Q2 		$4K Buy
+45
New +$30.3K ﹤0.01% 3817
2022
Q3 		– Sell
-11
Closed -$16K – 3667
2022
Q2 		$16K Sell
11
-3
-21% -$4.01K ﹤0.01% 3587
2022
Q1 		$29K Sell
14
-4
-22% -$10K ﹤0.01% 3630
2021
Q4 		$88K Hold
18
– – ﹤0.01% 3481
2021
Q3 		$113K Buy
18
+13
+260% +$105K ﹤0.01% 3394
2021
Q2 		$44K Buy
+5
New +$41.9K ﹤0.01% 3472
2018
Q2 		– Sell
-5
Closed -$55K – 2769
2018
Q1 		$55K Hold
5
– – ﹤0.01% 2588
2017
Q4 		$42K Hold
5
– – ﹤0.01% 2577
2017
Q3 		$11K Hold
5
– – ﹤0.01% 2554
2017
Q2 		$7K Hold
5
– – ﹤0.01% 2514
2017
Q1 		$9K Hold
5
– – ﹤0.01% 2409
2016
Q4 		$11K Buy
+5
New +$45.6K ﹤0.01% 2305

Other funds holding AVTX

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Vanguard Personalized Indexing Management
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.54B AUM 37.12% 1-Year Est. Return

Commonwealth Equity Services's AVTX Position: Q3 2023 in Review

Commonwealth Equity Services sold out of Avalo Therapeutics (AVTX) in Q3 2023, closing a stake of 45 shares — an estimated $4K sold.

Commonwealth Equity Services first reported a position in AVTX in Q4 2016 and held it in 12 quarters. The position peaked at $113K in Q3 2021. 24 funds tracked by Wall St. Rank hold AVTX as of Q3 2023.

  • Commonwealth Equity Services reported no remaining Avalo Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Commonwealth Equity Services sold 45 Avalo Therapeutics shares in Q3 2023, an estimated $4K.
  • Commonwealth Equity Services first reported a position in Avalo Therapeutics in Q4 2016 and held it in 12 quarters.
  • Commonwealth Equity Services's Avalo Therapeutics position peaked at $113K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2023.

Based on Commonwealth Equity Services's 13F filing for Q3 2023, filed 23 Oct 2023.